SBIR/STTR Research Award

Functional Tissue Engineering for Cartilage Repair

Award identifier d7659099dccb115c89b764064e0245dd9fd50ed6566ec744f26f5a2c4e2151ffAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$261,996

Program and phase

STTR · Phase I

Award year

2009

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Cytex Therapeutics, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
G9RMDCWJYGL3
Solicitation number
PHS2009-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Degenerative joint diseases such as osteoarthritis remain the source of significant pain and disability, affecting 20 million adults with an economic burden of over 40 billion per year to the United States. While joint replacement is a well-established procedure, its finite life span makes this treatment unacceptable for younger or more active individuals, often requiring additional surgeries that involve progressively complicated treatment with each joint replacement. The goal of this study is to develop a tissue engineered joint replacement from adult stem cells, derived via liposuction from subcutaneous fat, in combination with an engineered biomaterial scaffold to form a cartilage-bone composite to replace the entire surface of the hip joint. We will combine a novel three-dimensional (3D) fiber weaving technology with human adipose derived adult stem cells to create a layer of living cartilage and bone that can be used to completely replace a damaged joint surface. The primary advance of the current technology is the use of a 3D woven scaffold that nearly replicates the load-bearing mechanical properties of articular cartilage at the time of initial cell seeding, thus allowing rapid implantation without a prolonged in vitro culture period or use of a bioreactor. A defined combination of growth factors will be used initially to promote the differentiation of both bone and cartilage, followed by novel encapsulation and immobilization technologies to deliver these growth factors from the matrix in a local and sustained manner in vivo. The ultimate goal of this study is to develop technologies that can be applied to functional tissue engineering of a variety of tissues that possess complex biomechanical properties. As a first step, we will show proof- of-principal that composite, cell-seeded constructs can be fabricated with many of the complex mechanical properties of articular cartilage. The development of a 3-D weaving technology will hopefully provide a novel means of developing tissue engineered constructs that are biomechanically functional at the time of creation, through surgical implantation, and integration into host tissues in the body. An improved level of biomechanical function will hopefully increase the level of success in the engineered repair of various tissues of the musculoskeletal system as well as other organ systems of the body. PUBLIC HEALTH RELEVANCE: The goal of this Phase I STTR project is to develop a technology for bioartificial joint resurfacing as a treatment for hip osteoarthritis. The technologic basis involves a combination of adult stem cells, retrieved from subcutaneous fat via liposuction, and a novel three-dimensional woven scaffold that is designed to withstand joint loading. The ultimate goal of this study is to develop tissue engineering technologies that can eventually be used to treat osteoarthritis and other joint diseases.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

22 SBIR/STTR records share this UEI (2007–2023). Reported award amounts total $18,271,228. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services, National Science Foundation

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.